Welcome to LookChem.com Sign In|Join Free
  • or
KP 27303 is a chemical compound that belongs to the class of pyrazole derivatives. It is a white to off-white crystalline solid with a molecular formula of C15H14N4O2S and a molecular weight of 310.36 g/mol. KP 27303 is known for its potential applications in various fields, including pharmaceuticals and agrochemicals, where it may be used as an intermediate in the synthesis of other compounds. Due to its specific chemical structure, it can exhibit unique properties and reactivity, making it a subject of interest for researchers and chemists. However, it is important to note that the specific uses, safety, and environmental impact of KP 27303 would require further investigation and are not detailed in this summary.

6671-44-9

Post Buying Request

6671-44-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6671-44-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 6671-44-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,6,7 and 1 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 6671-44:
(6*6)+(5*6)+(4*7)+(3*1)+(2*4)+(1*4)=109
109 % 10 = 9
So 6671-44-9 is a valid CAS Registry Number.

6671-44-9Upstream product

6671-44-9Downstream Products

6671-44-9Relevant academic research and scientific papers

Antiproliferative 1,2,3-thiadiazole compounds

-

, (2008/06/13)

Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are 1,2,3-thiadiazoles having the structure: and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3 and R4 is independently selected from hydrogen, R5, R6, and R7; R5 is selected from alkyl, heteroalkyl, aryl and heteroaryl; R6 is selected from (R5)n-alkylene, (R5)n-heteroalkylene, (R5)n-arylene and (R5)n-heteroarylene; R7 is selected from (R6)n-alkylene, (R6)n-heteroalkylene, (R6)n-arylene, and (R6)n-heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R1 and R2 may together form a heterocyclic structure including the nitrogen to which they are both attached, and R3 and R4 may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L1 and L2 is independently selected from -A1-A2-A3- where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene.

Antiproliferative 1,2,3-thiadiazole compounds

-

, (2008/06/13)

Pharmaceutical compositions and compounds are provided. The compounds of the invention have anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, formulations of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical formulations are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are 1,2,3-thiadiazoles having the structure: and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R1, R2, R3and R4is independently selected from hydrogen, R5, R6, and R7; R5is selected from alkyl, heteroalkyl, aryl and heteroaryl; R6is selected from (R5)n-alkylene, (R5)n-heteroalkylene, (R5)n-arylene and (R5)n-heteroarylene; R7is selected from (R6)n-alkylene, (R6)n-heteroalkylene, (R6)n-arylene, and (R6)n-heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R1and R2may together form a heterocyclic structure including the nitrogen to which they are both attached, and R3and R4may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L1and L2is independently selected from —A1—A2—A3— where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 6671-44-9